The COVID-19 vaccine was on everyone's lips - Weekly Review, December 1 – 4

The COVID-19 vaccine was on everyone's lips - Weekly Review, December 1 – 4

A week full of partnerships and potential COVID-19 vaccine news

Monday and Tuesday: The rising number of COVID-19 infections in the city caused HongKong45 to trade 0.18% lower.

Even though the UK was the first country to approve a COVID-19 vaccine, its benchmark - UK100 - lost 1.6%.

EUR/USD went up 0.4% at 1.1976.

Year-to-date, ZOOM stock price went up 591%, the increase being mostly driven by the fact that people had to stay indoors amid the pandemic. In Q3 2020, the company reported revenues of $777.2 million on an adjusted EPS of 99 cents.

General Motors and Nikola announced their partnership through which the former will supply fuel cell systems to the latter. The deal is in force by the end of 2021. After the news hit the wire, GM stock price fell 1.7%.

Pfizer and BioNTech applied for conditional regulatory clearance in the European Union for their joint COVID-19 vaccine, BNT162b2. Following the news, Pfizer's stock price traded 2.92%, while BioNTech fell 2.61%.

Wednesday: The Reserve Bank of Australia announced that it would keep the interest rate unchanged, a decision which caused Australia200 to close 0.31% lower.

The latest deal in the beauty industry took place between Kohl's and Sephora. The agreement will allow Sephora to open at least 850 stores-in-stores by 2023. The markets applauded the news, with Kohl's gaining more than 13%.

Salesforce and Slack Technologies reached a consensus. The former will pay over $27 billion to purchase Slack, marking one of the most expensive transactions in the software industry. Slack stock price added 2.24% after the news.

It seems like more and more companies are leaving behind Silicon Valley. Hewlett Packard Enterprise is relocating to Houston after a better-than-expected Q4 2020 earnings report. Find out how the company performed here!

Thursday: In the US, the talks about a new stimulus package allegedly have been resumed, driving the benchmarks closing higher. USA30 went up 0.63%, while USA500 rose 0.30%. TECH100 traded 0.53% higher.

Snowflake stock price lost 8% even though the company reported Q3 2020 earnings that came ahead of the consensus. Its revenues grew 119%, reaching $159.6 million, while the losses per share were $1.01.

Splunk posted Q3 figures that were lower-than-expected. Its revenues came in at $558.6 million, with losses per share of $1.26. Following the news, the company's stock price traded 21% lower.

The US unemployment claims came in lower than the market has anticipated at 712,000. The consensus was 775,000.

Friday: Ulta Beauty reported Q3 2020 earnings that came ahead of estimates. The company had an EPS of $1.64 on revenues of $1.55 billion. Following the report, its stock price went up 2.67%.

Marvell Technologies lost 0.2% after it posted mixed quarterly Q3 2020 earnings. The EPS came in at 25 cents on revenues of $750 million.

As the number of COVID-19 infections increased, the number of non-farm payrolls decreased. In the past month, 245,000 jobs have been created in the US. At the same time, the unemployment rate fell to 6.7%.

Sources: investing.com, reuters.com, forexfactory.com, cnbc.com

This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com

JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.